If you have been reading about 白蛋白结合 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
=== Latin America === During World War II, the United States military operations had widespread support across Latin America, except for Argentina. After 1947, with the Cold War emerging in Europe, Washington made repeated efforts to encourage all the Latin American countries to take a Cold War anti-Communist position. They were reluctant to do so—for example, only Colombia sent soldiers to the United Nations Command in the Korean War. The Soviet Union was quite weak across Latin America. Not until the late 1950s did Moscow achieve diplomatic or commercial relationships with most Latin American countries., Before then it had only two trade agreements (with Argentina and Mexico). The communist movements that had existed in Brazil and elsewhere in the 1930s had been disbanded or outlawed. Washington exaggerated the dangers, and decided on a preemptive attack against a possible communist threat. It sought anti-communist resolutions at the annual meetings of the Pan American Union (renamed the Organization of American States (OAS) in 1948) and paid special attention to the growth of left-wing forces in Guatemala. A compromise was reached whereby the Latin American states agreed on vague statements of support for the American Cold War position, and the United States provided expanded financial grants and loans to stimulate economic growth. In 1954, at the 10th Inter-American Conference in Caracas, Washington demanded a resolution that the establishment of a communist government in any American state was a threat to the peace of the Western Hemisphere.
The Ordre des Palmes académiques (French pronunciation: [ɔʁdʁ de palm(z‿)akademik]; French for 'Order of Academic Palms') is a national order bestowed by the French Republic on distinguished academics and teachers and for valuable service to universities, education and science. Originally established in 1808 by Emperor of the French Napoleon as a decoration to honour eminent members of the University of Paris, it was changed into its current form as an order of merit on 4 October 1955 by President René Coty, making it one of the oldest civil honours bestowed by the French Republic.
Currently, very few methods are used to synthesize (S)-dapoxetine. This novel approach consists of only six steps in which three main steps are shown above. The initial reactant is trans-cinnamyl alcohol, which is commercially available. Sharpless asymmetric epoxidation and Mitsunobu reaction have been used to produce expected (S)-dapoxetine. The overall yield is 35%. This method is considered a good choice compared to the known methods due to high yield and easily obtainable reactants.
=== 1966 === January 31: Luna 9 is launched. February 3: Luna 9 successfully lands on the Moon becoming the first spacecraft to softly land on another extraterrestrial body. March 1: Venera 3 becomes the first man-made object to impact another planet. March 10: France withdraws from NATO command structure. March 11: President Sukarno of Indonesia signs a document, handing over authority to Major General Suharto. This led to Suharto later establishing the pro-western and anti-communist New Order regime. This regime would remain in power until 1998. May 8: Communist China detonates a third nuclear device. May 26: Guiana becomes independent from the UK under Commonwealth status. May 30: Surveyor 1 is launched. June 2: Surveyor 1 becomes the first American spacecraft to softly land on another extraterrestrial body. August 11: The Jakarta Accord is signed by the Indonesian Foreign Minister Adam Malik and Malaysian Deputy Prime Minister Tunku Abdul Razak ending the hostility between Indonesia and Malaysia. August 26: South African Border War begins. September 30: Bechuanaland renamed Botswana becomes independent from the UK. October 5: Beginning of low-level armed clashes in Korean DMZ between North Korea and South Korea backed by the United States. November 30: Barbados becomes independent from the UK.
Sources: en.wikipedia.org
=== EC 2.8.2: Sulfotransferases === EC 2.8.2.1: aryl sulfotransferase EC 2.8.2.2: alcohol sulfotransferase EC 2.8.2.3: amine sulfotransferase EC 2.8.2.4: estrone sulfotransferase EC 2.8.2.5: chondroitin 4-sulfotransferase EC 2.8.2.6: choline sulfotransferase EC 2.8.2.7: UDP-N-acetylgalactosamine-4-sulfate sulfotransferase EC 2.8.2.8: [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.9: tyrosine-ester sulfotransferase EC 2.8.2.10: Renilla-luciferin sulfotransferase EC 2.8.2.11: galactosylceramide sulfotransferase EC 2.8.2.12: deleted, identical to EC 2.8.2.8, [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.13: psychosine sulfotransferase EC 2.8.2.14: bile salt sulfotransferase EC 2.8.2.15: steroid sulfotransferase EC 2.8.2.16: thiol sulfotransferase EC 2.8.2.17: chondroitin 6-sulfotransferase EC 2.8.2.18: cortisol sulfotransferase EC 2.8.2.19: triglucosylalkylacylglycerol sulfotransferase EC 2.8.2.20: protein-tyrosine sulfotransferase EC 2.8.2.21: keratan sulfotransferase EC 2.8.2.22: aryl-sulfate sulfotransferase EC 2.8.2.23: [heparan sulfate]-glucosamine 3-sulfotransferase 1 EC 2.8.2.24: desulfoglucosinolate sulfotransferase EC 2.8.2.25: flavonol 3-sulfotransferase EC 2.8.2.26: quercetin-3-sulfate 3′-sulfotransferase EC 2.8.2.27: quercetin-3-sulfate 4′-sulfotransferase EC 2.8.2.28: quercetin-3,3′-bissulfate 7-sulfotransferase EC 2.8.2.29: [heparan sulfate]-glucosamine 3-sulfotransferase 2 EC 2.8.2.30: [heparan sulfate]-glucosamine 3-sulfotransferase 3 EC 2.8.2.31: petromyzonol sulfotransferase EC 2.8.2.32: scymnol sulfotransferase EC 2.8.2.33: N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase EC 2.8.2.34: glycochenodeoxycholate sulfotransferase EC 2.8.2.35: dermatan 4-sulfotransferase EC 2.8.2.36: desulfo-A47934 sulfotransferase EC 2.8.2.37: trehalose 2-sulfotransferase EC 2.8.2.38: aliphatic desulfoglucosinolate sulfotransferase EC 2.8.2.39: hydroxyjasmonate sulfotransferase EC 2.8.2.40: ω-hydroxy-β-dihydromenaquinone-9 sulfotransferase
The relatively quick heteronuclear single quantum correlation experiment helps determine the feasibility of doing subsequent longer, more expensive, and more elaborate experiments. It is not possible to assign peaks to specific atoms from the heteronuclear single quantum correlation alone.
Following a 15-month ATP-commissioned investigation conducted by The Lake Forest Group (a third-party consultant working with the ATP's outside legal counsel, Smith Hulsey & Busey), the ATP announced in late January 2023 that they would not punish Zverev due to insufficient evidence to substantiate the allegations.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.